ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn’s diseaseNew detailed data from the RELIEVE UCCD ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today presented new, detailed results from the RELIEVE UCCD phase 2b study of duvakitug, a human IgG1-λ2 ...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified ... Crohn’s and Colitis Organisation (ECCO) in Berlin, Germany.

Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...

French drug major Sanofi and the US unit of Israel’s Teva Pharmaceutical Industries have presented new, detailed results from the RELIEVE UCCD Phase IIb study of duvakitug, a human IgG1-λ2 monoclonal ...

Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...

The analyst will closely follow what Teva shares on this at the upcoming ECCO meeting ... Teva/Sanofi’s all-comers Phase III program for duvakitug is commercially reasonable, the goal is ...

The treatment landscape of Inflammatory Bowel Disease (IBD) has undergone a significant transformation over the past two ...

Following initial positive results shared by Teva and Sanofi in December 2024, new data shows duvakitug (TEV’574/SAR447189) ...

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified ... Crohn’s and Colitis Organisation (ECCO) in Berlin, Germany.